Imugene Ltd Reports Second Complete Response in BTKi Cohort [VIDEO]
Imugene's azer-cel has now recorded two complete responses from two evaluable patients in its BTKi cohort — including the first Mantle Cell Lymphoma patient treated — targeting a US$12 billion market where resistance to standard therapy leaves patients with almost nowhere left to turn.
Key Takeaways
- Both evaluable patients in Imugene's concurrent BTKi cohort have achieved complete responses at Day 28, including the first Mantle Cell Lymphoma patient treated in the study — a 100% CR rate in a heavily pre-treated population.
- Azer-cel is an off-the-shelf allogeneic CAR T therapy targeting CD19, deployable within days compared to the three-to-six-week manufacturing window required for autologous alternatives.
- The BTKi cohort targets patients who have already failed BTK inhibitor therapy — a growing population within a US$12.0 billion global BTKi market where resistance leaves patients with limited remaining options.
- Enrolment is active across ten US sites and five Australian sites, with Imugene indicating further data updates will be provided as the dataset matures but providing no specific timelines.
- The broader azer-cel Phase 1b basket program has previously reported a 100% ORR in CLL/SLL and 80% ORR in MZL, providing clinical context for the BTKi cohort's early complete response results.
![Genetic Signatures Ltd Gets BCAL Backing Through 10.2% Stake Purchase [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2Fb377bf6c-56e4-43e5-9dd1-8e08cd86e8c82Fimage_0.jpg)
![Algorae Pharmaceuticals Ltd Clarifies NSW Health Supply Panel Terms [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2Fbad3a004-c24a-4185-95c9-6312cede3da92Fimage_0.jpg)
![Algorae Pharmaceuticals Ltd Wins NSW Health Public Hospital Supply Contract [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2Fbc5a1876-b4d2-41c9-ba61-5ceb353457682Fimage_0.jpg)
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time
About the Publisher
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
Disclaimer
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
Disclosure
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.